Anthony J. Rothschild, MD

Utility of Combinatorial Pharmacogenomics in Depression

October 31, 2019

This study sought to ascertain the extent that pharmacogenetic testing can inform treatment decisions among patients with treatment-resistant depression whose medications are subject to gene-drug interactions—read the article to...

Michael E. Thase, Sagar V. Parikh, Anthony J. Rothschild, et al

Letter to the Editor

Benzodiazepines Do Not Cause Suicide or Suicide Attempts

October 5, 2017

Letter to the Editor: "Benzodiazepines Do Not Cause Suicide or Suicide Attempts"

Anthony J. Rothschild, Judith A Shindul-Rothschild

Article

Suicidality and Psychotic Depression Treatment Outcome

April 25, 2017

What role does suicidality have on the eventual effect of treatment in patients with psychotic depression? Read this report to explore the interaction of suicidality, randomized treatment assignment of...

Kathleen S. Bingham, Anthony J. Rothschild, Benoit H. Mulsant, et al

Article

Impaired Insight Into Delusions Predicts Treatment Outcome During a Randomized Controlled Trial for Psychotic Depression (STOP-PD Study)

April 22, 2015

Philip Gerretsen, Alastair J. Flint, Ellen M. Whyte, et al

Commentary

A Blood Test for Depression?

February 25, 2015

Anthony J. Rothschild

Original Research

Influence of Sex and Menopausal Status on Response, Remission, and Recurrence in Patients With Recurrent Major Depressive Disorder Treated With Venlafaxine Extended Release or Fluoxetine: Analysis of Data From the PREVENT Study

November 26, 2013

Susan G. Kornstein, Ronald D. Pedersen, Peter J. Holland, et al

Article

A Gender Analysis of the Study of Pharmacotherapy of Psychotic Depression (STOP-PD): Gender and Age as Predictors of Response and Treatment-Associated Changes in Body Mass Index and Metabolic Measures

October 15, 2013

Kristina M. Deligiannidis, Anthony J. Rothschild, Bruce A. Barton, et al

Original Research

Antidepressant Augmentation Using the N-Methyl-d-Aspartate Antagonist Memantine: A Randomized, Double-Blind, Placebo-Controlled Trial

October 15, 2013

Eric G. Smith, Kristina M. Deligiannidis, Christine M. Ulbricht, et al

Original Research

Missed Diagnosis of Psychotic Depression at 4 Academic Medical Centers

August 31, 2008

Anthony J. Rothschild, Jesse Winer, Alastair J. Flint, et al

Original Research

The Prevention of Recurrent Episodes of Depression With Venlafaxine for Two Years (PREVENT) Study: Outcomes From the 2-Year and Combined Maintenance Phases

August 15, 2007

Martin B. Keller, Madhukar H. Trivedi, Michael E. Thase, et al

Original Research

Prevention of Recurrent Episodes of Depression With Venlafaxine ER in a 1-Year Maintenance Phase From the PREVENT Study

July 16, 2007

James H. Kocsis, Michael E. Thase, Madhukar H. Trivedi, et al

Original Research

Persisting Low Use of Antipsychotics in the Treatment of Major Depressive Disorder With Psychotic Features

February 15, 2007

Carmen Andreescu, Benoit H. Mulsant, Catherine Peasley-Miklus, et al

Utility of Combinatorial Pharmacogenomics in Depression

Benzodiazepines Do Not Cause Suicide or Suicide Attempts

Suicidality and Psychotic Depression Treatment Outcome

Impaired Insight Into Delusions Predicts Treatment Outcome During a Randomized Controlled Trial for Psychotic Depression (STOP-PD Study)

A Blood Test for Depression?

Influence of Sex and Menopausal Status on Response, Remission, and Recurrence in Patients With Recurrent Major Depressive Disorder Treated With Venlafaxine Extended Release or Fluoxetine: Analysis of Data From the PREVENT Study

A Gender Analysis of the Study of Pharmacotherapy of Psychotic Depression (STOP-PD): Gender and Age as Predictors of Response and Treatment-Associated Changes in Body Mass Index and Metabolic Measures

Antidepressant Augmentation Using the N-Methyl-d-Aspartate Antagonist Memantine: A Randomized, Double-Blind, Placebo-Controlled Trial

Missed Diagnosis of Psychotic Depression at 4 Academic Medical Centers

The Prevention of Recurrent Episodes of Depression With Venlafaxine for Two Years (PREVENT) Study: Outcomes From the 2-Year and Combined Maintenance Phases

Prevention of Recurrent Episodes of Depression With Venlafaxine ER in a 1-Year Maintenance Phase From the PREVENT Study

Persisting Low Use of Antipsychotics in the Treatment of Major Depressive Disorder With Psychotic Features

ELSEWHERE:

FOLLOW US:

Anthony J. Rothschild, MD

Utility of Combinatorial Pharmacogenomics in Depression

Benzodiazepines Do Not Cause Suicide or Suicide Attempts

Suicidality and Psychotic Depression Treatment Outcome

Impaired Insight Into Delusions Predicts Treatment Outcome During a Randomized Controlled Trial for Psychotic Depression (STOP-PD Study)

A Blood Test for Depression?

Influence of Sex and Menopausal Status on Response, Remission, and Recurrence in Patients With Recurrent Major Depressive Disorder Treated With Venlafaxine Extended Release or Fluoxetine: Analysis of Data From the PREVENT Study

A Gender Analysis of the Study of Pharmacotherapy of Psychotic Depression (STOP-PD): Gender and Age as Predictors of Response and Treatment-Associated Changes in Body Mass Index and Metabolic Measures

Antidepressant Augmentation Using the N-Methyl-d-Aspartate Antagonist Memantine: A Randomized, Double-Blind, Placebo-Controlled Trial

Missed Diagnosis of Psychotic Depression at 4 Academic Medical Centers

The Prevention of Recurrent Episodes of Depression With Venlafaxine for Two Years (PREVENT) Study: Outcomes From the 2-Year and Combined Maintenance Phases

Prevention of Recurrent Episodes of Depression With Venlafaxine ER in a 1-Year Maintenance Phase From the PREVENT Study

Persisting Low Use of Antipsychotics in the Treatment of Major Depressive Disorder With Psychotic Features

Celebrating85 Years

Subscribe to readmore articles

Celebrating
85 Years

Subscribe to read
more articles